Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by
blocking the enzymes necessary for cancer cell growth. Combining chemotherapy with imatinib
mesylate may kill more cancer cells.
PURPOSE: Phase I/II trial to study the effectiveness of combining arsenic trioxide with
imatinib mesylate in treating patients who have chronic phase chronic myelogenous leukemia.